Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Immune cells and their inflammatory mediators modify β cells and cause checkpoint inhibitor–induced diabetes
Ana Luisa Perdigoto, Songyan Deng, Katherine Du, et al.
JCI Insight (2022) Vol. 7, Iss. 17
Open Access | Times Cited: 28

Showing 1-25 of 28 citing articles:

Risk Factors and Characteristics of Checkpoint Inhibitor–Associated Autoimmune Diabetes Mellitus (CIADM): A Systematic Review and Delineation From Type 1 Diabetes
Linda Wu, Venessa Tsang, Alexander M. Menzies, et al.
Diabetes Care (2023) Vol. 46, Iss. 6, pp. 1292-1299
Open Access | Times Cited: 26
Toxicity in the era of immune checkpoint inhibitor therapy
Synat Keam, Naimah Turner, Fernanda G. Kugeratski, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 14
Tislelizumab-induced type 1 diabetic ketoacidosis in a patient with small cell lung cancer: a case report
Jie Zhu, Wenjie Wang
Frontiers in Oncology (2025) Vol. 15
Open Access | Times Cited: 1
Immune‐related adverse events after immune check point inhibitors: Understanding the intersection with autoimmunity
Namrata Singh, Anne M. Hocking, Jane H. Buckner
Immunological Reviews (2023) Vol. 318, Iss. 1, pp. 81-88
Closed Access | Times Cited: 21
Laser‐Activatable In Situ Vaccine Enhances Cancer‐Immunity Cycle
Zhenyu Wang, Tingting You, Qianyi Su, et al.
Advanced Materials (2023) Vol. 35, Iss. 52
Closed Access | Times Cited: 18
Immune-Checkpoint Inhibitors-Induced Type 1 Diabetes Mellitus: From Its Molecular Mechanisms to Clinical Practice
Yun Kyung Cho, Chang Hee Jung
Diabetes & Metabolism Journal (2023) Vol. 47, Iss. 6, pp. 757-766
Open Access | Times Cited: 16
Dominant Expression of Chromogranin B in Pituitary Corticotrophs and Its Putative Role in Interaction With Secretogranin III
Shota Kikuchi, Kyuto Odashima, Tadashi Yasui, et al.
Journal of Histochemistry & Cytochemistry (2025)
Open Access
Clinicopathologic Characteristics of Immune Checkpoint Inhibitor-related Pancreatitis
Feidi Chen, Monika Vyas, Matthew Gosse, et al.
The American Journal of Surgical Pathology (2025)
Closed Access
Immune checkpoint inhibitors: From friend to foe
Prem Rajak
Toxicology Reports (2025), pp. 102033-102033
Open Access
Germline genetic variants are associated with development of insulin-dependent diabetes in cancer patients treated with immune checkpoint inhibitors
Jasmine I. Caulfield, Lilach Aizenbud, Ana Luisa Perdigoto, et al.
Journal for ImmunoTherapy of Cancer (2023) Vol. 11, Iss. 3, pp. e006570-e006570
Open Access | Times Cited: 10
Rare, late onset of immune checkpoint inhibitor-induced type 1 diabetes mellitus in a patient with small-cell lung cancer treated with serplulimab: a case report and review of the literature
Peng Ning, Shilan Liu, Hongyi Cao
Journal of Medical Case Reports (2024) Vol. 18, Iss. 1
Open Access | Times Cited: 3
The impact of apelin-13 on cisplatin-induced endocrine pancreas damage in rats: an in vivo study
Serpil Çiftel, Levent Tümkaya, Sinan Saral, et al.
Histochemistry and Cell Biology (2024) Vol. 161, Iss. 5, pp. 391-408
Closed Access | Times Cited: 3
Incidence of diabetes mellitus in patients treated with immune checkpoint inhibitors (ICI) therapy – A comprehensive cancer center experience
Zhen Zhang, Rajeev Sharma, Lamya Hamad, et al.
Diabetes Research and Clinical Practice (2023) Vol. 202, pp. 110776-110776
Closed Access | Times Cited: 9
Gut microbiota mediate the alleviation effect of Xiehuo-Guzheng granules on β cell dedifferentiation in type 2 diabetes mellitus
Zebiao Cao, Xianzhe Wang, Huijun Liu, et al.
Phytomedicine (2024) Vol. 135, pp. 156151-156151
Closed Access | Times Cited: 2
Stocking the toolbox—Using preclinical models to understand the development and treatment of immune checkpoint inhibitor‐induced immune‐related adverse events
Morgan L. Cina, Jessica Shade Venegas, Arabella Young
Immunological Reviews (2023) Vol. 318, Iss. 1, pp. 110-137
Open Access | Times Cited: 4
A case of rapidly progressive insulin-dependent diabetes mellitus without islet autoantibodies developed over two years after the first dose of nivolumab
Kota Nishihama, Yuko Okano, Chisa Inoue, et al.
Diabetology International (2024) Vol. 15, Iss. 3, pp. 583-588
Closed Access | Times Cited: 1
Immune checkpoint inhibitor‑associated diabetes mellitus in patients with HCC: Report of three cases and literature review
Gaocheng Wang, Jingjing Wang, Shuilin Dong, et al.
Experimental and Therapeutic Medicine (2024) Vol. 27, Iss. 5
Open Access | Times Cited: 1
Comparative Analysis of Epigallocatechin-3-Gallate and TNF-Alpha Inhibitors in Mitigating Cisplatin-Induced Pancreatic Damage Through Oxidative Stress and Apoptosis Pathways
Enver Çiftel, Filiz Mercantepe, Tolga Mercantepe, et al.
Biological Trace Element Research (2024) Vol. 202, Iss. 11, pp. 5190-5207
Open Access | Times Cited: 1
UTX Epigenetically Imposes a Cytolytic Effector Program in Autoreactive Stem-like CD8+ T cell Progenitors
Ho-Chung Chen, H. Wang, Lisa A. Kohn, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 1
Multiscale geometric and topological analyses for characterizing and predicting immune responses from single cell data
Aarthi Venkat, Dhananjay Bhaskar, Smita Krishnaswamy
Trends in Immunology (2023) Vol. 44, Iss. 7, pp. 551-563
Closed Access | Times Cited: 3
Successful treatment of nivolumab and ipilimumab triggered type 1 diabetes by using sodium-glucose transporter 2 inhibitor: a case report and systematic review
Makoto Fujiwara, Masaru Shimizu, Tatsuya Okano, et al.
Frontiers in Public Health (2023) Vol. 11
Open Access | Times Cited: 3
New insights into the characteristics of DRAK2 and its role in apoptosis: From molecular mechanisms to clinically applied potential
Youwei Zheng, Xinchao Li, Lirun Kuang, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 5
Immune checkpoint inhibitor– and phosphatidylinositol-3-kinase inhibitor–related diabetes induced by antineoplastic drugs: two case reports and a literature review
Yue Gao, Mingyao Zhong, Lulu Gan, et al.
Frontiers in Endocrinology (2023) Vol. 14
Open Access | Times Cited: 2
Pancreatic Islet Cells Response to IFNγ Relies on Their Spatial Location within an Islet
Marine De Burghgrave, Chloé Lourenço, Claire Berthault, et al.
Cells (2022) Vol. 12, Iss. 1, pp. 113-113
Open Access | Times Cited: 4
Research Advances of Immune Checkpoint Inhibitors Related Endocrine Adverse Events
晶晶 王
Advances in Clinical Medicine (2024) Vol. 14, Iss. 02, pp. 2706-2716
Closed Access
Page 1 - Next Page

Scroll to top